IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Intriguingly CARMIL2 can also work in a dominant mode, as a gain-of-function mutation (Q575E) has been linked to cutaneous T cell lymphoma, selectively upregulating the NF-κB pathway and causing activated T cells to significantly increase their IL-2 production (19).